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Background: Liposarcoma is the most frequent soft tissue sarcoma. Well differentiated liposarcoma may progress
into dedifferentiated liposarcoma with pleomorphic histology. A minority additionally features myogenic, osteo- or
chondrosarcomatous heterologous differentiation. Genomic amplification of the Mouse double minute 2 homolog
(MDM2) locus is characteristic for well differentiated and dedifferentiated liposarcomas. Detection of MDM2
amplification may supplement histopathology and aid to distinguish liposarcoma from other soft tissue neoplasia.
Case presentation: Here we present two cases of dedifferentiated liposarcoma with challenging presentation. Case 1
features a myogenic component. As the tumour infiltrated the abdominal muscles and showed immunohistochemical
expression of myogenic proteins, rhabdomyosarcoma had to be ruled out. Case 2 has an osteosarcomatous
component resembling extraosseous osteosarcoma. The MDM2 status was determined in both cases and helped
making the correct diagnosis. Overexpression of MDM2 and co-overexpression of Cyclin-dependent kinase 4 is
demonstrated by immunohistochemistry. The underlying MDM2 amplification is shown by fluorescence in situ
hybridisation. Since low grade osteosarcoma may also harbour MDM2 amplification it is emphasised that the
amplification has to be present in the lipomatous parts of the tumour to distinguish liposarcoma from extraosseous
osteosarcoma.
Conclusions: The two cases exemplify challenges in the diagnoses of dedifferentiated liposarcoma. Liposarcoma
often has pleomorphic histology and additionally may feature heterologous components that mimic other soft
tissue neoplasms. Amplification of MDM2 is characteristic for well differentiated and dedifferentiated liposarcomas.
Determination of the MDM2 status by in situ hybridisation may assist histopathology and help to rule out
differential diagnoses.
Keywords: Dedifferentiated Liposarcoma, Liposarcoma with osteoblastic component, MDM2, Fluorescence in situ
hybridisationBackground
Liposarcoma (LS) is the most common soft tissue sarcoma
with about 20% [1]. They are categorized into five
subtypes according to WHO classification [2,3] (Table 1).
The majority are well differentiated liposarcomas/atypical
lipomatous tumours (ALT; 40%). About 10% progress to* Correspondence: scheel@patho-nordhessen.de
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unless otherwise stated.dedifferentiated liposarcoma [3] (DDLPS). LS are usually
located in the deep soft tissue. ALT are most frequently lo-
cated in the limbs, particularly the thighs while DDLPS
are most frequent in the retroperitoneum. LS affect adults,
the incidence peaks around 60 years.
Histomorphology of DDLPS usually shows remains of
ALT with an abrupt shift to dedifferentiated neoplastic tis-
sue. The dedifferentiated tissue is most commonly non
lipogenic and pleomorphic, reminiscent of undifferentiated
pleomorphic sarcoma (formerly called malignant fibrous
histiocytoma). Additionally, heterologous differentiationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Benign and malignant lipomatous tumors as listed by the current WHO-definition and MDM2-status
Entity Dignity ICD-O MDM2 amplified
Lipoma Benign 8850/0 no
Lipoblastoma Benign 8851/0 no
Angiolipoma Benign 8861/0 no
Myolipoma Benign 8890/0 no
Chondroid lipoma Benign 8862/0 no
Spindle cell lipoma Benign 8854/0 no
Pleomorphic lipoma Benign 8854/0 no
Hibernoma Benign 8880/0 no
Well differentiated liposarcoma/atypical lipomatous tumor Intermediate, locally aggressive 8851/1 yes
Dedifferentiated liposarcoma Malignant 8858/3 yes
Myxoid liposacroma Malignant 8852/3 no
Pleomorphic liposarcoma Malignant 8854/3 no
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myogenic, osteo/chondrosarcomatous or angiosarcoma-
tous [4]. Thus DDLPS may mimic a broad spectrum of
soft tissue tumours. The clinical prognosis of DDLPS is
better than for other high grade sarcoma and is not
affected by the presence of heterologous differentiation.
A hallmark of ALT and DDLPS is the genomic amplifi-
cation of the MDM2 gene [5]. This can be detected by
fluorescence in situ hybridization (FISH) and may facilitate
diagnosis [6].
In this report we present two cases of DDLPS with
challenging presentations. Both tumours featured heter-
ologous components imitating other soft tissue sarcoma.
MDM2 amplification was detected by FISH and helped
to rule out potential differential diagnosis.
Case presentation
Case #1, clinical presentation
An 84 year old male obese (BMI 35 kg/m2) patient pre-
sented with chronic anaemia, localized right abdominal
pain and loss of appetite. A CT-scan unmasked a 4.2 ×
2.7 × 7 cm hypodense (50HU) solid mass in the painful
abdominal region [Figure 1A]. Staging laparoscopy was
performed and revealed a whitish tumour in the sub-
cutaneous fatty tissue. The adjacent abdominal skeletal
muscles were infiltrated while the peritoneum was not
compromised and the abdominal cavity was inconspicu-
ous. Biopsies were taken and routine histology showed a
malignant mesenchymal neoplasm. After discussion in
an interdisciplinary tumour board wide resection with
the aim of complete tumour removal was performed.
The tumour region including the path of the laparos-
copy, adjacent skin and peritoneum, inguinal canal and
ductus deferens were removed en-bloc. The abdominal
wall was reconstructed using an intraperitoneal onlay
mesh graft technique (IPOM). Histological finding revealeddisseminated tumour growth into the cranio-lateral
margin (R1). Reoperation yielded a complete tumour
removal (R0). The patient recovered and was dis-
charged from hospital 13 days after initial surgery.
Soon after the patient was readmitted with ileus due to
abdominal adhesions. Laparoscopy was performed and
a 35 cm long small intestine segment was removed.
Histology did not show any further tumour infiltrates.
The patient recovered well and was in good health one
year later.
Histologic and molecular findings
On gross examination the 13 × 10.5 × 6 cm specimen
contained a 7 × 3.5 × 3.1 cm tumour with whitish/pale
yellow cut surfaces [Figure 1B]. The tumour was mostly
well delimited with focal areas of diffuse transition into
the surrounding tissue. Haematoxylin and eosin (HE)
staining showed a neoplasm with high cellularity and
mostly spindle-shaped cells arranged in storiform pat-
terns (Figure 2B). Focal transition into more well differ-
entiated atypical adipose tissue were present (2A). Parts
of the tumour showed myofibroblastic morphology with
parallel, slender cells (2C). Immunohistochemistry (IHC)
revealed coexpression of Actin and Desmin (2D) while
Caldesmon and Myogenin were negative.
Neoplastic giant cells with nuclear vacuoles were present
(Figure 3) and IHC stainings for CDK4 and MDM2 were
positive (3B, C). Fluorescence in situ hybridization with a
MDM2-specific probe (ZytoLight SPEC MDM2/CEN12
dual colour probe; ZytoVision, Bremerhaven, Germany)
was supplemented. Groups of highly amplified MDM2
clusters were detected in all parts of the tumour (3D).
Given morphologic and molecular findings, the neo-
plasm was identified as dedifferentiated liposarcoma
with myofibroblastic component (ICD-O: C49.4 M8858/3
G3 (FNCLCC)).
Figure 1 Clinical presentation of Case #1: Preoperative CT-scan (A) of the tumour in the lower left abdominal wall. Macroscopic
presentation of the surgical specimen (B); central parts of the tumour are well delimited ('core'); the path of the primary laparoscopy is visible.
The tumour infiltrated the abdominal skeletal muscles but did not extra into the abdominal cavity.
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A 66 year old male patient presented with acute abdomen.
The pain was pronounced in the lower right abdomen.
Emergency surgery was performed and revealed a rup-
tured cystic mass of the lower right abdominal wall withFigure 2 Histopathology of Case #1: The tumour shows patches of hi
displays only poorly differentiated spindle-shaped cells (B). Prominent
immunohistochemistry was positive for Desmin (D) and Actin.connection to the abdominal cavity. En bloc resection was
performed. The mass was found to be contained in the
soft tissue without connection to the pelvic bones. Given
the emergency situation and rupture, excision in toto
could not be guaranteed.gher differentiated atypical lipomatous tissue (A) but mostly
areas with myofibroblastic morphology were noticed (C) and
Figure 3 Molecular hallmarks of Case #1: Immunohistochemistry demonstrates co-overexpression of CDK4 (B) and MDM2 (C) in both
the poorly and higher differentiated areas (A: HE-staining of corresponding region). Fluorescence in situ hybridisation shows strong
amplification of the MDM2 locus as underlying genetic alteration (D; Green: MDM2 probe, Red: Chromosome 12 reference probe). The features
are characteristic of dedifferentiated liposarcoma.
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Gross examination showed a 20 × 9 × 2.5 cm specimen
with yellow-whitish, smooth surface. Cross sections showed
soft and fatty tissue. The wall showed areas with solid,
partially mineralized tissue with lamellar macroscopic
appearance.
HE stainings showed a mesenchymal proliferation with
high cellularity and mixed morphology (Figure 4): TheFigure 4 Histopathology and molecular hallmarks of Case #2: The tum
spindle-shaped but giant cells with segmented nuclei were also present. Fo
noticed (A). Other areas were of osteoblastic/osteosarcomatous (B) and fib
the MDM2 gene revealed highly amplified clusters in the lipomatous (D, lecells were mostly of spindle-shaped appearance with high
pleomorphy. Giant cells with segmented nuclei were
present. Mitoses and few atypical mitoses were observed
besides areas with no mitotic activity. Transitions into
more differentiated fatty tissue were found (Figure 4A)
as well as areas with osteoblastic/osteosarcomatous (4B)
and fibrosarcomatous appearance (4C). FISH of the
MDM2 gene revealed highly amplified clusters in theour showed heterogeneous morphology. Most cells were
cally, transitions into higher differentiated lipomatous tissue were
rosarcomatous appearance (C). Fluorescence in situ hybridisation of
ft), fibrosarcomatous and the osteosarcomatous regions (D, right).
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tous regions (4D, ZytoLight SPEC MDM2/CEN12 dual
colour probe). The tumour was identified as dedifferen-
tiated liposarcoma with heterologous differentiation
(ICD-O: C49.4 M8858/3 G2 (FNCLCC)).
Course of disease
The patient was transferred to a medical centre special-
ized in abdominal and plastic surgery. Wide excision of
the tumour area was performed about one month after
initial surgery. Intraoperative two tumours on the small
intestine were noticed and excised. Histology confirmed
tumour implants of the liposarcoma both of which had
been locally excised in sano. The patient recovered from
the extended surgical procedures and no signs of recur-
rent disease were detectable during follow-up CT- and
ultrasound-scans one year later.
Conclusions
Two cases of neoplasm of the lower abdominal wall were
resolved as dedifferentiated liposarcomas. Each tumour
featured mixed morphology, one with myofibroblastic and
one with osteoblastic component. Histopathology was
supplemented with detailed immunohistochemistry and in
situ hybridization for MDM2. Both tumours showed high
MDM2 amplification which is an almost pathognomonic
finding given the localization and age of the patients.
ALT and DDLPS usually show a characteristic genomic
amplification of 12q13-15 including the proto-oncogenes
MDM2 (12q14.3-15) and CDK4 (12q14). Amplification
may be detected by comparative genome hybridization or
by FISH. CDK4 is often coamplified with MDM2 and the
gene products may be detected by IHC. Ubiquitin ligase
MDM2 accelerates protosomal degradation of master
tumour suppressor protein p53 while cell cycle associated
kinase CDK4 phosphorylates and activates the retinoblast-
oma gene product (Rb) [7,8]. Physiologically CDK4 is itself
activated by D cyclines during G1 progression and inhib-
ited by p16 (INK4a). Conversely p53 point mutations are
rarely found in ALT and DDLPS.
The most widely used technique to determine the
MDM2 status is currently dual colour FISH. Two probes
specific for 12q14 and for the centromeric region of
chromosome 12 are employed to detect amplification or
polysomy. Cases are dichotomously classified by the ratio
of MDM2 to centrosome; ≥2.0 are regarded as amplified
and <2.0 as non-amplified. At least 50 non overlapping
neoplastic cells should be counted [6]. In our own hands
application of the threshold is usually not required since
ALT and DDLPS invariably show high amplifications with
clusters of >10 copies [Figures 2D, 3D].
Sensitivity of the FISH analysis has been reported to
be 93.5%-100% in a case-dependent manner [6,9]. It also
has a high specificity in distinguishing lipoma from ALT.Benign lipomatous lesions do not harbour MDM2 am-
plifications [6,10]. Spindle cell lipoma are reported to
frequently have chromosome 12 polysomy [6] while ALT
and DDLPS close to always show MDM2 amplifications.
On the other hand, myxoid liposarcomas and most
pleomorphic liposarcomas do not harbour MDM2 am-
plifications. An exception from the rule of thumb that
pleomorphic liposarcomas are MDM2 negative are cu-
taneous and subcutanous pleomorphic liposarcoma
which may be MDM2 amplified in very rare cases [11].
A recent study could demonstrate that peripheral undif-
ferentiated sarcomas with MDM2 amplification corres-
pond to DDLPS, even if a well-differentiated component
was not present [12].
Overall, few non-liposarcomatous tumours are known
to have increased MDM2 gene copy numbers. Most not-
ably low grade osteosarcoma arising on the surface of bone
may feature 12q14 amplifications [13] while extraosseous
osteosarcoma are complex genomic sarcoma without
recurrent MDM2 amplifications.
The two cases exemplify challenges in the diagnosis of
DDLPS. Case #1 showed little remaining well differenti-
ated liposarcomatous tissue and featured a myogenic com-
ponent. Therefore, most important differential diagnosis
was rhabdomyosarcoma. Localisation, epidemiology and
molecular findings render this possibility unlikely: IHC for
Myogenin was negative and the MDM2 amplification is
not observed in tumours of myogenic origin.
Case #2 featured a striking osteosarcomatous compo-
nent which could also reflect presence of an extraoss-
eous osteosarcoma. Given the localisation close to a
fascia ossifying myositis would be benign second differ-
ential diagnoses. Transitions into atypical lipomatous
tissue were noticed and under the hypotheses of DDLPS
hybridisation for MDM2 was performed. Low grade
Osteosarcoma (OS) may also harbour amplified MDM2.
Thus, the detection of MDM2-amplification in the
osteosarcomatous parts is not suited to distinguish
between low grade OS and DDLPS. However, the ampli-
fication in our case was present in all parts of the
tumour, including the atypical adipocytes. Thus the ma-
lignant character of the atypical adipose tissue, i.e. the
liposarcomatous tissue was confirmed. Also, the tumour
did not have contact to bone and extraosseous OS do
not harbourMDM2 amplifications. Thus, the combination
of patient age, localisation, morphology and MDM2 status
strongly argues for the osteosarcomatous tissue to be
heterologous component of a DDLPS.
The current standard therapy of DDLPS is wide exci-
sion. No consensus exists about the minimal length of the
resection margins and the widest resection possible should
be archived [14]. This is particularly challenging in the
retroperitoneum which may explain the high rates of
local recurrences of DDLPS (20-100% depending on the
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in 15-20% of cases while ALT do not metastasise [2].
Case #2 exemplifies that scattered DDLPS tissue may
easily spawn tumour implants. Both patients were in
good health one year after treatment and showed no
signs of recurrent disease. However, given the slow-
growing behaviour of DDLPS careful follow-up investi-
gations are necessary.
The recurrent MDM2 amplification might be a key
to targeted therapy of DDLPS: Experimental MDM2-
inhibitors have been successfully employed in vitro to
reactivate p53 and mediate apoptosis [15]. While the
first generation of MDM2 inhibitors proved to be clinic-
ally intolerable several newly developed substances are
currently undergoing phase I trials. Should they translate
into approved drugs the MDM2 status might become a
predictive biomarker.
Keypoints
Liposarcoma is the most frequent soft tissue neoplasm.
About 40% are well differentiated liposarcoma which may
progress into dedifferentiated liposarcoma. The clinical
prognosis is better compared to other high grade soft
tissue sarcoma.
Dedifferentiated liposarcoma has pleomorphic histo-
morphology. The diagnosis is facilitated by the demon-
stration of remaining well differentiated liposarcomatous
tissue.
A minority of cases may present a heterologous differen-
tiation of myogenic, osteo-/chondrosarcomatous or angio-
sarcomatous appearance. These have to be distinguished
from sarcoma of other origin.
Detection of MDM2 and CDK4 amplification and coex-
pression by FISH and IHC has a high specificity and may
support classification of challenging cases.
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